Cargando…

Cancer Vaccines Co-Targeting HER2/Neu and IGF1R

(1) Background: Human epidermal growth factor receptor 2 (HER2)/neu-driven carcinogenesis is delayed by preventive vaccines able to elicit autochthonous antibodies against HER2/neu. Since cooperation between different receptor tyrosine kinases (RTKs) can occur in human as well as in experimental tum...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Giovanni, Carla, Landuzzi, Lorena, Palladini, Arianna, Ianzano, Marianna Lucia, Nicoletti, Giordano, Ruzzi, Francesca, Amici, Augusto, Croci, Stefania, Nanni, Patrizia, Lollini, Pier-Luigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520928/ https://www.ncbi.nlm.nih.gov/pubmed/30979001 http://dx.doi.org/10.3390/cancers11040517

Ejemplares similares

Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis
por: De Giovanni, Carla, et al.
Publicado: (2019)

Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis
por: Croci, Stefania, et al.
Publicado: (2015)

Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice
por: Ianzano, Marianna L., et al.
Publicado: (2013)

OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis
por: Nanni, Patrizia, et al.
Publicado: (2018)

HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy
por: De Giovanni, Carla, et al.
Publicado: (2021)

Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2
por: De Giovanni, Carla, et al.
Publicado: (2014)

Preclinical Therapy of Disseminated HER-2(+) Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus
por: Nanni, Patrizia, et al.
Publicado: (2013)

Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression
por: Giusti, Veronica, et al.
Publicado: (2021)

Multiorgan Metastasis of Human HER-2(+) Breast Cancer in Rag2(−/−);Il2rg(−/−) Mice and Treatment with PI3K Inhibitor
por: Nanni, Patrizia, et al.
Publicado: (2012)

Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model
por: De Giovanni, Carla, et al.
Publicado: (2019)

Cancer immunoprevention: from mice to early clinical trials
por: Palladini, Arianna, et al.
Publicado: (2018)

IFN-γ and CD38 in Hyperprogressive Cancer Development
por: Angelicola, Stefania, et al.
Publicado: (2021)

HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response
por: Palladini, Arianna, et al.
Publicado: (2017)

Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas
por: Landuzzi, Lorena, et al.
Publicado: (2014)

Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice
por: Nanni, Patrizia, et al.
Publicado: (2001)

Interleukin 12–mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice
por: Boggio, Katia, et al.
Publicado: (1998)

Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations
por: Nanni, Patrizia, et al.
Publicado: (2019)

Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft
por: Landuzzi, Lorena, et al.
Publicado: (2021)

Virus-like particle display of HER2 induces potent anti-cancer responses
por: Palladini, Arianna, et al.
Publicado: (2018)

Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational Research
por: Landuzzi, Lorena, et al.
Publicado: (2023)

Human responses against HER-2-positive cancer cells in human immune system-engrafted mice
por: De Giovanni, C, et al.
Publicado: (2012)

Preclinical HER-2 Vaccines: From Rodent to Human HER-2
por: Lollini, Pier-Luigi, et al.
Publicado: (2013)

Prevention and Therapy of Metastatic HER-2(+) Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine
por: Ruzzi, Francesca, et al.
Publicado: (2022)

Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy
por: Ruzzi, Francesca, et al.
Publicado: (2023)

Modeling the competition between lung metastases and the immune system using agents
por: Pennisi, Marzio, et al.
Publicado: (2010)

Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases
por: Leoni, Valerio, et al.
Publicado: (2015)

ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC
por: Ruzzi, Francesca, et al.
Publicado: (2022)

CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality
por: Sorrentino, Carlo, et al.
Publicado: (2022)

Intradermal DNA Electroporation Induces Cellular and Humoral Immune Response and Confers Protection against HER2/neu Tumor
por: Lamolinara, Alessia, et al.
Publicado: (2015)

Evaluation of Modified PEG-Anilinoquinazoline Derivatives as Potential Agents for EGFR Imaging in Cancer by Small Animal PET
por: Pantaleo, Maria A., et al.
Publicado: (2010)

Patient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma
por: Landuzzi, Lorena, et al.
Publicado: (2021)

Innovative Breakthroughs for the Treatment of Advanced and Metastatic Synovial Sarcoma
por: Landuzzi, Lorena, et al.
Publicado: (2023)

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET
por: Pantaleo, Maria Abbondanza, et al.
Publicado: (2010)

Induction of myogenic differentiation in human rhabdomyosarcoma cells by ionising radiation, N,N-dimethylformamide and their combination.
por: Nicoletti, G., et al.
Publicado: (1992)

Targeting Glutathione-S Transferase Enzymes in Musculoskeletal Sarcomas: A Promising Therapeutic Strategy
por: Pasello, Michela, et al.
Publicado: (2011)

2011: the immune hallmarks of cancer
por: Cavallo, Federica, et al.
Publicado: (2011)

The Promise of Preventive Cancer Vaccines
por: Lollini, Pier-Luigi, et al.
Publicado: (2015)

HER-2/neu diagnostics in breast cancer
por: Carney, Walter P, et al.
Publicado: (2007)

The Clinical Importance of the Heterogeneity of HER2 neu
por: Davila, Enrique, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_833lhp4r99smnhn7q2880e5rf7